Lisocabtagene maraleucel对比标准治疗(挽救性化疗序贯自体干细胞移植)用于复发或难治性大B细胞淋巴瘤二线治疗(TRANSFORM):开放标签随机3期试验中期分析结果
TRANSFORM研究比较liso-cel与标准治疗(铂类挽救免疫化疗后自体HSCT)用于原发难治或早期复发(≤12个月)大B细胞淋巴瘤的二线治疗。中期分析显示liso-cel组中位无事件生存期10.1个月,标准治疗组2.3个月(分层HR 0.35,95%CI 0.23-0.53,单侧p<0.0001)。
要点
- liso-cel组中位EFS为10.1个月,标准治疗组为2.3个月,分层HR 0.35
- liso-cel组3级及以上中性粒细胞减少80%,标准治疗组51%
- liso-cel组3级细胞因子释放综合征和神经系统事件分别占1%和4%
核心结论
- 这些结果支持liso-cel作为早期复发或难治性大B细胞淋巴瘤患者新的二线治疗推荐。
研究设计与样本
- TRANSFORM为全球3期研究,在美国、欧洲和日本47个中心开展,比较liso-cel与标准治疗作为原发难治或早期(≤12个月)复发大B细胞淋巴瘤的二线治疗。
- 入组患者为18-75岁、ECOG体能状态评分≤1、器官功能充分、符合Lugano 2014标准PET阳性病灶、适合自体HSCT的成人,按1:1随机分配至liso-cel(100×10^6 CAR+ T细胞静脉输注)或标准治疗。
- 标准治疗包括3周期静脉挽救免疫化疗(R-DHAP、R-ICE或R-GDP),应答者后续接受大剂量化疗和自体HSCT。
- 主要终点为无事件生存期,由独立审查委员会按Lugano 2014标准评估应答;疗效按意向治疗人群分析,安全性在接受了任何治疗的患者中分析。
主要发现
- 2018年10月23日至2020年12月8日筛查232例患者,184例随机分配至liso-cel组(n=92)或标准治疗组(n=92)。
- 截至2021年3月8日数据截止,中位随访6.2个月(IQR 4.4-11.5)。
- liso-cel组中位无事件生存期为10.1个月(95%CI 6.1-未达到),标准治疗组为2.3个月(95%CI 2.2-4.3),分层风险比0.35(95%CI 0.23-0.53),分层Cox比例风险模型单侧p<0.0001。
- 最常见的3级或更严重不良事件:中性粒细胞减少(liso-cel组92例中74例[80%] vs 标准治疗组91例中46例[51%])、贫血(45例[49%] vs 45例[49%])、血小板减少(45例[49%] vs 58例[64%])、持续性血细胞减少(40例[43%] vs 3例[3%])。
- liso-cel组3级细胞因子释放综合征和神经系统事件分别发生于92例中的1例(1%)和4例(4%)(无4级或5级事件)。
临床怎么用
- 作者认为,这些结果支持liso-cel作为早期复发或难治性大B细胞淋巴瘤患者新的二线治疗推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of care, platinum-based salvage immunochemotherapy and autologous haematopoietic stem cell transplantation (HSCT). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL. METHODS: TRANSFORM is a global, phase 3 study, conducted in 47 sites in the USA, Europe, and Japan, comparing liso-cel with standard of care as second-line therapy in patients with primary refractory or early (≤12 months) relapsed LBCL. Adults aged 18-75 years, Eastern Cooperative Oncology Group performance status score of 1 or less, adequate organ function, PET-positive disease per Lugano 2014 criteria, and candidates for autologous HSCT were randomly assigned (1:1), by use of interactive response technology, to liso-cel (100 × 106 CAR+ T cells intravenously) or standard of care. Standard of care consisted of three cycles of salvage immunochemotherapy delivered intravenously-R-DHAP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, two infusions of cytarabine 2000 mg/m2 on day 2, and cisplatin 100 mg/m2 on day 1), R-ICE (rituximab 375 mg/m2 on day 1, ifosfamide 5000 mg/m2 on day 2, etoposide 100 mg/m2 on days 1-3, and carboplatin area under the curve 5 [maximum dose of 800 mg] on day 2), or R-GDP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, gemcitabine 1000 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1)-followed by high-dose chemotherapy and autologous HSCT in responders. Primary endpoint was event-free survival, with response assessments by an independent review committee per Lugano 2014 criteria. Efficacy was assessed per intention-to-treat (ie, all randomly assigned patients) and safety in patients who received any treatment. This trial is registered with ClinicalTrials.gov, NCT03575351, and is ongoing. FINDINGS: Between Oct 23, 2018, and Dec 8, 2020, 232 patients were screened and 184 were assigned to the liso-cel (n=92) or standard of care (n=92) groups. At the data cutoff for this interim analysis, March 8, 2021, the median follow-up was 6·2 months (IQR 4·4-11·5). Median event-free survival was significantly improved in the liso-cel group (10·1 months [95% CI 6·1-not reached]) compared with the standard-of-care group (2·3 months [2·2-4·3]; stratified hazard ratio 0·35; 95% CI 0·23-0·53; stratified Cox proportional hazards model one-sided p<0·0001). The most common grade 3 or worse adverse events were neutropenia (74 [80%] of 92 patients in the liso-cel group vs 46 [51%] of 91 patients in the standard-of-care group), anaemia (45 [49%] vs 45 [49%]), thrombocytopenia (45 [49%] vs 58 [64%]), and prolonged cytopenia (40 [43%] vs three [3%]). Grade 3 cytokine release syndrome and neurological events, which are associated with CAR T-cell therapy, occurred in one (1%) and four (4%) of 92 patients in the liso-cel group, respectively (no grade 4 or 5 events). Serious treatment-emergent adverse events were reported in 44 (48%) patients in the liso-cel group and 44 (48%) in the standard-of-care group. No new liso-cel safety concerns were identified in the second-line setting. There were no treatment-related deaths in the liso-cel group and one treatment-related death due to sepsis in the standard-of-care group. INTERPRETATION: These results support liso-cel as a new second-line treatment recommendation in patients with early relapsed or refractory LBCL. FUNDING: Celgene, a Bristol-Myers Squibb Company.
引用
- Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022. PMID: 35717989. doi:10.1016/S0140-6736(22)00662-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。